Trial Profile
A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Heparin; Warfarin
- Indications Embolism; Stroke; Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMANATE
- Sponsors Pfizer
- 06 Apr 2018 Primary endpoint (Number of Participants With All Cause Death) has not been met as per the results published in the European Heart Journal.
- 06 Apr 2018 Primary endpoint (Number of Participants With Acute Stroke Event) has been met as per the results published in the European Heart Journal.
- 06 Apr 2018 Results published in the European Heart Journal